DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Medroxyprogesterone (Medroxyprogesterone Acetate) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

Changes in Contraceptive Effectiveness Associated with Coadministration of Other Products

If a woman on hormonal contraceptives takes a drug or herbal product that induces enzymes, including CYP3A4, that metabolize contraceptive hormones, counsel her to use additional contraception or a different method of contraception. Drugs or herbal products that induce such enzymes may decrease the plasma concentrations of contraceptive hormones, and may decrease the effectiveness of hormonal contraceptives. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include:

  • barbiturates
  • bosentan
  • carbamazepine
  • felbamate
  • griseofulvin
  • oxcarbazepine
  • phenytoin
  • rifampin
  • St. John’s wort
  • topiramate

 

HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors

Significant changes (increase or decrease) in the plasma levels of progestin have been noted in some cases of co-administration of HIV protease inhibitors. Significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of co-administration with non-nucleoside reverse transcriptase inhibitors.

Antibiotics

There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids.

Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.

Laboratory Test Interactions

The pathologist should be advised of progestin therapy when relevant specimens are submitted.

The following laboratory tests may be affected by progestins including medroxyprogesterone acetate injectable suspension:

(a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol,

pregnanediol, testosterone, cortisol).

(b) Gonadotropin levels are decreased.

(c) Sex-hormone-binding-globulin concentrations are decreased.

(d) Protein-bound iodine and butanol extractable protein-bound iodine may increase.

T3-uptake values may decrease.

(e) Coagulation test values for prothrombin (Factor II), and Factors VII, VIII, IX, and

X may increase.

(f) Sulfobromophthalein and other liver function test values may be increased.

(g) The effects of medroxyprogesterone acetate on lipid metabolism are inconsistent.

Both increases and decreases in total cholesterol, triglycerides, low-density

lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol

have been observed in studies.

CONTRAINDICATIONS

The use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions:

  • Known or suspected pregnancy or as a diagnostic test for pregnancy.
  • Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see Warnings and Precautions (5.2)].
  • Known or suspected malignancy of breast [see Warnings and Precautions (5.3)].
  • Known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see Warnings and Precautions (5.5)].
  • Significant liver disease [see Warnings and Precautions (5.6)].
  • Undiagnosed vaginal bleeding [see Warnings and Precautions (5.9)].

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017